Compare GNS & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GNS | XBIT |
|---|---|---|
| Founded | 2002 | 2005 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Pharmaceuticals and Biotechnology |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.8M | 73.2M |
| IPO Year | 2022 | 2015 |
| Metric | GNS | XBIT |
|---|---|---|
| Price | $0.67 | $2.51 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.7M | 63.5K |
| Earning Date | 09-23-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,749,894.00 | N/A |
| Revenue This Year | $82.78 | N/A |
| Revenue Next Year | $85.90 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.21 | $2.09 |
| 52 Week High | $1.92 | $6.66 |
| Indicator | GNS | XBIT |
|---|---|---|
| Relative Strength Index (RSI) | 49.42 | 52.78 |
| Support Level | $0.62 | $2.40 |
| Resistance Level | $0.76 | $2.55 |
| Average True Range (ATR) | 0.06 | 0.14 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 52.91 | 57.89 |
Genius Group Ltd is an Edtech and education company that provides entrepreneur education system business development tools and management consultancy services to entrepreneurs and entrepreneur resorts. The company's business consists of two reportable business segments: Education, which involves entrepreneur education, management consultancy, and business development tools; and Campus, consisting of resorts, retreats, and co-working cafes for entrepreneurs. It derives the majority of its revenue from the Education segment. Geographically, it operates in Europe/Middle East/Africa, Asia/Pacific, and North America/South America. The company derives maximum revenue from Europe/Middle East/Africa.
XBiotech Inc is a United States-based clinical-stage biopharmaceutical company. The company is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-inflammatory therapeutic antibodies as a treatment for cancer. Geographically, all of its operations are in the United States.